The FDA will require makers of GLP-1 receptor agonist drugs, including Ozempic, Wegovy, Zepbound and Mounjaro, to add a warning about a "potential increased risk" of a rare eye condition that can cause permanent vision loss.
The agency announced the change in a drug safety communication on Monday. The condition is non-arteritic anterior ischemic optic neuropathy, or NAION. It starts when blood flow to the optic nerve is restricted, which causes swelling and cell death. The result is abrupt vision loss that can often be permanent. How GLP-1 drugs might trigger it is unknown.
NAION is uncommon. According to the American Academy of Ophthalmologists, it occurs in somewhere between two and 10 people per 100,000 in the general population. Cases that rare are hard to count, and that makes a connection to any single drug hard to confirm.
A second problem is overlap. The risk factors for NAION include diabetes, cardiovascular disease, high blood pressure, high cholesterol, metabolic syndrome and obstructive sleep apnea. Those are common among people who take GLP-1 drugs, so it is hard to separate what the drugs do from what the underlying conditions do.
That context shapes how to read the label change. The FDA's wording is "potential," and the mechanism is unexplained. A label warning in this setting looks like a precaution taken while the evidence is incomplete, not a finding that the drugs cause NAION. The open question is whether further data can pull the drugs' effect apart from the health conditions that so often come with them.